Integrated Filing — IndAS



General information about company
Scrip Code 532851
NSE Symbol INSECTICID
MSEI Symbol NA
ISIN INE070I01018
Name of company Insecticides (India) Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 28-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-Mar-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Agro-chemicals
Start date and time of board meeting 28-May-2025   14:00:00
End date and time of board meeting 28-May-2025   15:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-10
Indicate Company website link for updated RPT policy of the Company https://insecticidesindia.com/wp-content/uploads/2025/05/Revised-Related-Party-Transaction-Policy-10022025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NIL



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3591451000 20022658000
Other income 29354000 72258000
Total income 3620805000 20094916000
2 Expenses
(a) Cost of materials consumed 3273106000 13551402000
(b) Purchases of stock-in-trade 121955000 751127000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1109952000 -638916000
(d) Employee benefit expense 281528000 1371570000
(e) Finance costs 20177000 67232000
(f) Depreciation, depletion and amortisation expense 71361000 290475000
(f) Other Expenses
1 Other expenses 740117000 2799177000
Total other expenses 740117000 2799177000
Total expenses 3398292000 18192067000
3 Total profit before exceptional items and tax 222513000 1902849000
4 Exceptional items 0 0
5 Total profit before tax 222513000 1902849000
6 Tax expense
7 Current tax 122243000 553915000
8 Deferred tax -39979000 -48722000
9 Total tax expenses 82264000 505193000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 140249000 1397656000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 140249000 1397656000
17 Other comprehensive income net of taxes -7763000 -12797000
18 Total Comprehensive Income for the period 132486000 1384859000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 290978000 290978000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 10526925000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.82 47.61
Diluted earnings (loss) per share from continuing operations 4.82 47.61
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.82 47.61
Diluted earnings (loss) per share from continuing and discontinued operations 4.82 47.61
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above Audited Standalone Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 28, 2025. The auditors of the company have carried out the audit of the same. The Audit Report along with Financial Results for the quarter and year ended March 31, 2025 are available on the Stock Exchanges website at www.bseindia.com, www.nseindia.com and on the Company website www.insecticidesindia.com 3. The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz Agro-Chemicals comprising of Technical & Formulation. 5. The Board of Directors of Insecticides (India) Limited at its meeting held on August 09, 2024 had approved the dissolution/ liquidation of its wholly owned subsidiary IIL Overseas DMCC, Dubai. Accordingly, IIL Overseas DMCC has filed the application for windup / dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) for which approval is yet to be received as of March 31, 2025. 6. The Board of Directors of the Company, at its meeting held on November 11, 2024, approved the acquisition of 100% equity shares of Kaeros Research Private Limited (Target Company) from its existing shareholders through a share purchase agreement (SPA) between the existing shareholders and the Company. Consequently, target company becomes the wholly owned subsidiary of Insecticides (India) Limited. 7. The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year up to 31 March 2025 and the unaudited published year-to-date figures up to 31 December 2024 being the date of the end of the third quarter of the financial year which were subjected to a limited review. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2298129000
Capital work-in-progress 1559924000
Investment property 10467000
Goodwill 0
Other intangible assets 85275000
Intangible assets under development 49854000
Biological assets other than bearer plants 0
Investments accounted for using equity method 182355000
Non-current financial assets
Non-current investments 82218000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 26732000
Total non-current financial assets 108950000
Deferred tax assets (net) 13272000
Other non-current assets 450867000
Total non-current assets 4759093000
2 Current assets
Inventories 8826801000
Current financial asset
Current investments 0
Trade receivables, current 3856791000
Cash and cash equivalents 553801000
Bank balance other than cash and cash equivalents 11811000
Loans, current 2501000
Other current financial assets 85147000
Total current financial assets 4510051000
Current tax assets (net) 0
Other current assets 780052000
Total current assets 14116904000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 18875997000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 290978000
Other equity 10526925000
Total equity attributable to owners of parent 10817903000
Non controlling interest
Total equity 10817903000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 234724000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 26460000
Total non-current financial liabilities 261184000
Provisions, non-current 54460000
Deferred tax liabilities (net) 48663000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 364307000
Current liabilities
Current financial liabilities
Borrowings, current 755174000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 225029000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4777729000
Total Trade payable 5002758000
Other current financial liabilities 493899000
Total current financial liabilities 6251831000
Other current liabilities 1305591000
Provisions, current 48359000
Current tax liabilities (Net) 88006000
Deferred government grants, Current 0
Total current liabilities 7693787000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 8058094000
Total equity and liabilites 18875997000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Changes in fair value of FVTOCI equity instruments 3126000 -3071000
2 Remeasurement of net defined benefit plans -13577000 -13952000
3 Income tax relating to these items 2688000 4226000
Total Amount of items that will not be reclassified to profit and loss -7763000 -12797000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -7763000 -12797000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1902849000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 67232000
Adjustments for decrease (increase) in inventories -762198000
Adjustments for decrease (increase) in trade receivables, current -943430000
Adjustments for decrease (increase) in trade receivables, non-current -1062000
Adjustments for decrease (increase) in other current assets 40055000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current -3054000
Adjustments for other financial assets, current -76376000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 847101000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -120797000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 290475000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 684000
Adjustments for provisions, current 25904000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 35662000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 2283000
Adjustments for interest income 23545000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 79795000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -545837000
Net cash flows from (used in) operations 1357012000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 410796000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 946216000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 82427000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 26187000
Purchase of property, plant and equipment 356861000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets -232000
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 2218000
Interest received 23545000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -387106000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 618802000
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 285760000
Repayments of borrowings 133112000
Payments of lease liabilities 22041000
Dividends paid 59196000
Interest paid 68445000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -615836000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -56726000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -56726000
Cash and cash equivalents cash flow statement at beginning of period 610527000
Cash and cash equivalents cash flow statement at end of period 553801000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S S Kothari Mehta & Co., LLP Yes 31-Aug-2025
2 Devesh Parekh & Co Yes 29-Feb-2028


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Insecticides (India) Limited Hari Chand Aggarwal Chairman / KMP Remuneration 0 No adverse Remark 46088000 1474000 1165000
2 Insecticides (India) Limited Rajesh Kumar Aggarwal Managing Director / KMP Remuneration 0 No adverse Remark 46124000 1307000 1095000
3 Insecticides (India) Limited Nikunj Aggarwal Whole-time Director / KMP Remuneration 0 No adverse Remark 2560000 611000 491000
4 Insecticides (India) Limited Anil Kumar Goyal Whole-time Director / KMP Remuneration 0 No adverse Remark 769000 224000 174000
5 Insecticides (India) Limited Sandeep Aggarwal Chief Financial Officer / KMP Remuneration 0 No adverse Remark 2448000 699000 474000
6 Insecticides (India) Limited Sandeep Kumar Company Secreatary / KMP Remuneration 0 No adverse Remark 1532000 496000 337000
7 Insecticides (India) Limited Sanskar Aggarwal Relative of KMP Remuneration 0 No adverse Remark 1438000 329000 280000
8 Insecticides (India) Limited Sanjeev Aggarwal Relative of KMP Remuneration 0 No adverse Remark 1528000 511000 326000
9 Insecticides (India) Limited Praveen Gupta Independent Director Any other transaction Sitting fees 0 No adverse Remark 415000 0 0
10 Insecticides (India) Limited Anil Kumar Bhatia Independent Director Any other transaction Sitting fees 0 No adverse Remark 415000 0 0
11 Insecticides (India) Limited Sonia Aggarwal Relative of KMP Any other transaction Consultancy fees 3000000 No adverse Remark 548000 84000 84000
12 Insecticides (India) Limited Anju Aggarwal Relative of KMP Remuneration 0 No adverse Remark 900000 275000 232000
13 Insecticides (India) Limited Pushpa Aggarwal Relative of KMP Any other transaction Rent Paid 6900000 No adverse Remark 582000 0 0
14 Insecticides (India) Limited ISEC Organics Limited Directors and Directors relatives holding more than 2% Any other transaction Rent Paid 100000000 No adverse Remark 308000 0 0
15 Insecticides (India) Limited IIL Foundation Trust in whichnPromoter is anTrustee Any other transaction Corporate Social Responsibility 25200000 No adverse Remark 12600000 0 0
16 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Purchase of goods or services 100000000 No adverse Remark 31806000 7248000 5221000
17 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Any other transaction Rental Income 100000000 No adverse Remark 955000 0 0
18 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Sale of goods or services 100000000 No adverse Remark 5337000 4041000 2643000
19 Insecticides (India) Limited IIL Biologicals Limited Wholly-owned Subsidiary Any other transaction Reimbursement of expenses 100000000 No adverse Remark 154000 0 0
20 Insecticides (India) Limited Kaeros Research Pvt Ltd Wholly-owned Subsidiary Purchase of goods or services 1000000000 No adverse Remark 217443000 48092000 22520000
21 Insecticides (India) Limited Kaeros Research Pvt Ltd Wholly-owned Subsidiary Any other transaction Rental Income 1000000000 No adverse Remark 2203000 0 0
22 Insecticides (India) Limited Kaeros Research Pvt Ltd Wholly-owned Subsidiary Sale of goods or services 1000000000 No adverse Remark 15278000 5369000 970000
23 Insecticides (India) Limited Kaeros Research Pvt Ltd Wholly-owned Subsidiary Any other transaction Corporate Guarantee Fee (OFA) 1000000000 No adverse Remark 5900000 0 4900000
24 Insecticides (India) Limited Kaeros Research Pvt Ltd Wholly-owned Subsidiary Any other transaction Reimbursement of expenses 1000000000 No adverse Remark 98000 0 0
25 Insecticides (India) Limited ISEC Organics Limited Directors and Directors relatives holding more than 2% Any other transaction Advance received back 100000000 No adverse Remark 13061000 33386000 20326000
26 Insecticides (India) Limited Valve & Pneumatics Directors Relatives holding more than 2% Purchase of goods or services 60000000 No adverse Remark 0 0 0
27 Insecticides (India) Limited IIL Overseas DMCC (Dubai) Wholly-owned Subsidiary Any other transaction Reimbursement of expesnse 100000000 No adverse Remark 0 429000 429000
28 Insecticides (India) Limited OAT & IIL India Laboratories Private Limited Joint Venture (Enterprises over which the Company exercises joint control) Purchase of goods or services 150000000 No adverse Remark 17692000 15233000 -5000
29 Insecticides (India) Limited OAT & IIL India Laboratories Private Limited Joint Venture (Enterprises over which the Company exercises joint control) Any other transaction Deputation fee Income 150000000 No adverse Remark 2054000 927000 0
30 Insecticides (India) Limited OAT & IIL India Laboratories Private Limited Joint Venture (Enterprises over which the Company exercises joint control) Any other transaction Revenue from Manopower supply 150000000 No adverse Remark 2209000 0 0
31 Insecticides (India) Limited Vinod Metal Industries Directors Relatives holding more than 2% Purchase of goods or services 60000000 No adverse Remark 14922000 8907000 6940000
32 Insecticides (India) Limited Indogulf Cropsciences Ltd. Directors Relatives holding more than 2% Purchase of goods or services 150000000 No adverse Remark 2468000 0 0
33 Insecticides (India) Limited Indogulf Cropsciences Ltd. Directors Relatives holding more than 2% Sale of goods or services 150000000 No adverse Remark 13591000 21753000 13592000
34 Insecticides (India) Limited Crystal Crop Protection Ltd. Directors Relatives holding more than 2% Purchase of goods or services 500000000 No adverse Remark 143824000 90598000 107164000
35 Insecticides (India) Limited Crystal Crop Protection Ltd. Directors Relatives holding more than 2% Sale of goods or services 500000000 No adverse Remark 52264000 2124000 39735000
36 Insecticides (India) Limited HPM Chemicals and Fertilizers Ltd. Directors Relatives holding more than 2% Purchase of goods or services 250000000 No adverse Remark 69909000 14723000 9654000
37 Insecticides (India) Limited HPM Chemicals and Fertilizers Ltd. Directors Relatives holding more than 2% Sale of goods or services 250000000 No adverse Remark 40710000 0 7533000
38 Insecticides (India) Limited Crop Care Federation of India KMP is the Director Any other transaction Subscription fees 4500000 No adverse Remark 885000 885000 885000
39 Insecticides (India) Limited IIL Employee Gratuity Trust Post Employment Benefit Trust Any other transaction Any other transaction 0 No adverse Remark 0 0 0
40 Insecticides (India) Limited Sanskar Aggarwal Relative of KMP Any other transaction Purchase of Equity Shares of Kaeros Research P Ltd 0 No adverse Remark 1371000 0 0
41 Insecticides (India) Limited Rajesh Kumar Aggarwal Managing Director / KMP Any other transaction Purchase of Equity Shares of Kaeros Research P Ltd 0 No adverse Remark 40094000 0 0
42 Insecticides (India) Limited Nikunj Aggarwal Whole-time Director / KMP Any other transaction Purchase of Equity Shares of Kaeros Research P Ltd 0 No adverse Remark 20961000 0 0
43 Insecticides (India) Limited Shyam Lal Bansal Independent Director Any other transaction Sitting fees 0 No adverse Remark 455000 0 0
44 Insecticides (India) Limited Supratim Bandyopadhyay Independent Director Any other transaction Sitting fees 0 No adverse Remark 415000 0 0
45 Insecticides (India) Limited Navin shah Independent Director Any other transaction sitting fees 0 No adverse Remark 0 0 0
46 Insecticides (India) Limited Virjesh kumar Gupta Independent Director Any other transaction sitting fees 0 No adverse Remark 0 0 0
47 Insecticides (India) Limited Jayaraman Independent Director Any other transaction sitting fees 0 No adverse Remark 0 0 0
48 Insecticides (India) Limited Kaeros Research Pvt Ltd Wholly-owned Subsidiary Any other transaction Corporate guarantee/letter of comfort 100000000 No adverse Remark 500000000 0 500000000
Total value of transaction during the reporting period 1334314000